CA3226758A1 - Compounds and compositions for the treatment of coronaviral related diseases - Google Patents
Compounds and compositions for the treatment of coronaviral related diseases Download PDFInfo
- Publication number
- CA3226758A1 CA3226758A1 CA3226758A CA3226758A CA3226758A1 CA 3226758 A1 CA3226758 A1 CA 3226758A1 CA 3226758 A CA3226758 A CA 3226758A CA 3226758 A CA3226758 A CA 3226758A CA 3226758 A1 CA3226758 A1 CA 3226758A1
- Authority
- CA
- Canada
- Prior art keywords
- carbonitrile
- isoquinolin
- oxoimidazolidine
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224793P | 2021-07-22 | 2021-07-22 | |
| US63/224,793 | 2021-07-22 | ||
| US202163289009P | 2021-12-13 | 2021-12-13 | |
| US63/289,009 | 2021-12-13 | ||
| PCT/IB2022/056712 WO2023002409A1 (en) | 2021-07-22 | 2022-07-20 | Compounds and compositions for the treatment of coronaviral related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226758A1 true CA3226758A1 (en) | 2023-01-26 |
Family
ID=82742919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226758A Pending CA3226758A1 (en) | 2021-07-22 | 2022-07-20 | Compounds and compositions for the treatment of coronaviral related diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250092016A1 (enExample) |
| EP (1) | EP4373814A1 (enExample) |
| JP (1) | JP2024527424A (enExample) |
| KR (1) | KR20240038996A (enExample) |
| AU (1) | AU2022315058A1 (enExample) |
| CA (1) | CA3226758A1 (enExample) |
| MX (1) | MX2024000986A (enExample) |
| PY (1) | PY2261702A (enExample) |
| TW (1) | TW202321210A (enExample) |
| UY (1) | UY39863A (enExample) |
| WO (1) | WO2023002409A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| TWI925033B (zh) | 2020-10-16 | 2026-05-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| AU2023249953A1 (en) | 2022-04-08 | 2024-10-24 | Shionogi & Co., Ltd. | Uracil derivative having viral growth inhibitory activity and pharmaceutical composition containing same |
| AU2023303408A1 (en) | 2022-07-06 | 2024-12-19 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| CR20250040A (es) | 2022-08-05 | 2025-03-18 | Gilead Sciences Inc | Inhibidores de la proteasa principal de sars-cov2 |
| WO2025125695A2 (en) * | 2024-12-17 | 2025-06-19 | Medchemica Consultancy Ltd | Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1200825B (de) * | 1962-01-13 | 1965-09-16 | Hoechst Ag | Verfahren zur Herstellung von 3, 5-Dioxo-triazolidinen |
| PE20121048A1 (es) * | 2009-06-26 | 2012-08-25 | Novartis Ag | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 |
-
2022
- 2022-07-19 UY UY0001039863A patent/UY39863A/es unknown
- 2022-07-19 PY PY202202261702A patent/PY2261702A/es unknown
- 2022-07-19 TW TW111127023A patent/TW202321210A/zh unknown
- 2022-07-20 MX MX2024000986A patent/MX2024000986A/es unknown
- 2022-07-20 CA CA3226758A patent/CA3226758A1/en active Pending
- 2022-07-20 AU AU2022315058A patent/AU2022315058A1/en active Pending
- 2022-07-20 WO PCT/IB2022/056712 patent/WO2023002409A1/en not_active Ceased
- 2022-07-20 US US18/580,986 patent/US20250092016A1/en active Pending
- 2022-07-20 KR KR1020247005669A patent/KR20240038996A/ko active Pending
- 2022-07-20 JP JP2024503613A patent/JP2024527424A/ja active Pending
- 2022-07-20 EP EP22748094.4A patent/EP4373814A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022315058A1 (en) | 2024-02-08 |
| MX2024000986A (es) | 2024-02-12 |
| WO2023002409A1 (en) | 2023-01-26 |
| UY39863A (es) | 2023-02-28 |
| US20250092016A1 (en) | 2025-03-20 |
| EP4373814A1 (en) | 2024-05-29 |
| PY2261702A (es) | 2023-06-14 |
| KR20240038996A (ko) | 2024-03-26 |
| TW202321210A (zh) | 2023-06-01 |
| JP2024527424A (ja) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250092016A1 (en) | Compounds and compositions for the treatment of coronaviral related diseases | |
| US10544133B2 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
| US10913738B2 (en) | Aminotriazolopyridines as kinase inhibitors | |
| CN110016020B (zh) | 化合物或其药学上可接受的盐及其应用和药物组合物 | |
| CN104922128B (zh) | 流感病毒复制抑制剂 | |
| CN107089985B (zh) | 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物 | |
| EP3180344A1 (en) | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase | |
| CA2917193A1 (en) | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators | |
| JP6739516B2 (ja) | 呼吸器合胞体ウイルス阻害剤 | |
| AU2022255486A1 (en) | Nek7 inhibitors | |
| WO2022224223A1 (en) | Compounds and compositions for the treatment of coronaviral related diseases | |
| JP2010519328A (ja) | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用 | |
| JP2023540548A (ja) | 抗腫瘍活性を有する化合物及びその使用 | |
| CA3074059A1 (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
| WO2021202775A1 (en) | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as sstr4 agonists | |
| EA050666B1 (ru) | Соединения и композиции для лечения заболеваний, связанных с коронавирусной инфекцией | |
| CN117651699A (zh) | 用于治疗冠状病毒相关疾病的化合物和组合物 | |
| WO2026075941A1 (en) | Pyridazinone derivatives as pad4 inhibitors | |
| HK40075584A (en) | Kv3 enhancers for the treatment of cognitive disorders | |
| HK1243063B (en) | Pyrrolo [2, 3-d] pyrimidine derivatives as inhibitors of janus-related kinases (jak) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250617 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250617 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260615 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260615 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260615 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260616 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260616 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260618 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260722 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260722 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260722 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260722 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260722 |